Manufacturing Decisions That Shape mRNA Clinical Success
- Confusing your platform with solid ground can lead to clinical stumbles
- Yield that ignores RNA integrity or impurity directly reduce potency or increase reactogenicity
- Capping efficiency and the Poly-A tail are clinical levers, not just a spec